Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply

N Engl J Med. 2019 Nov 21;381(21):2076-2077. doi: 10.1056/NEJMc1913157.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Glucagon-Like Peptides
  • Humans
  • Hypoglycemic Agents

Substances

  • Hypoglycemic Agents
  • semaglutide
  • Glucagon-Like Peptides